Your SlideShare is downloading. ×
2.1. Pharmaceutical in the Environment: An Evidence-based Review: Introduction (Ruhoy)
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Saving this for later?

Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime - even offline.

Text the download link to your phone

Standard text messaging rates apply

2.1. Pharmaceutical in the Environment: An Evidence-based Review: Introduction (Ruhoy)

380
views

Published on

By Ilene Ruhoy. …

By Ilene Ruhoy.

This slidecast is part of the GreenPharmEdu.org program.

Published in: Health & Medicine

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
380
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Pharmaceutical In the Environment:
    An Evidence-based Review
    Ilene S. Ruhoy, M.D., PhD
    Director, Institute for Environmental Medicine
    Touro University Nevada
    Henderson, Nevada 89014
    Ilene.ruhoy@tun.touro.edu
    Source: US Environmental Protection Agency. Paul Horn, Union Tribute. Retrieved from: http://www.flickr.com/photos/cooljerk/219637528/#/
  • 2. Course Objectives
    1
    Review current research
    on pharmaceutical residues found in water sampling studies.
    2
    Understand the various sources
    of pharmaceuticals in the environment.
    3
    4
    Discuss the ecological impact
    of pharmaceuticals in the environment.
    Examine the potential
    for human health impact from exposure to pharmaceutical residues.
  • 3. Sections
    Pharmaceuticals as Chemicals
    Significance of long-term exposure to multiple APIs
    Evidence for ecotoxity
    Environmental Impact of Disposal
    PharmEcovigilance
    Reducing Unused Pharmaceuticals
    Conclusion
  • 4. Pharmaceuticals as Chemicals
  • 5. Stockpiling &
    improper storage
    Leftover Drugs
    Imprudent prescribing & patient use
    Imprudent disposal
    Residues recycled from environment
    Wasted healthcare resources
    Poisonings
  • 6. The Chemical Universe
    We live in a chemical sea of continually changing composition
    – comprising both anthropogenic and naturally occurring chemical stressors.
    Unlike biota, chemical pollutants have no boundaries in their global distribution – “everything is everywhere,” only the concentrations vary.
  • 7. The Chemical Universe
    The KNOWNUniverse
    As of Sept. 2009, over 50 million organic and inorganic substances had been assigned CAS RNs.*
    • 35 million commercially available
    • 8. ¼ million inventoried or regulated by numerous government bodies worldwide
    • 9. Representing:0.7% of commercially available0.5% of the known chemicals.
    • 10. 12,000new substances are added each day.
    * Indexed by the American Chemical Society's Chemical Abstracts Service in their CAS Registry; excluding bio-sequences such as
    proteins and nucleotides: http://www.cas.org/expertise/cascontent/registry/regsys.html
  • 11. The Chemical Universe
    The largest virtual chemical database yet reported comprises small drug-like molecules – a total of over 977,000,000 structures (Blum and Reymond, 2009).
    Restricted to organic molecules containing fewer than 14 atoms of C, N, O, and S (and limited types of Cl-substituted molecules). Excluded likely substituents such as F, Br, I, P, Si, metals, and most Cl.
    Database represents the enormously large numbers of chemicals that could possibly be synthesized just from a very limited spectrum of types of elements and numbers of atoms.
    Source: Blum, L. C., and J.-L. Reymond. 2009. 970 Million Druglike Small Molecules for Virtual Screening in the Chemical Universe Database GDB-13. J. Am. Chem. Soc. 131 (25):8732-8733.
  • 12. The Universe of Commercial APIs
    • Over 21,000 formulated drug products (ingredients, strengths, and forms)
    • 13. Over 1,460 FDA-approved small-molecule APIs(oral >80, parenteral >420, topical >270)
    • 14. Over 3,200 experimental drugs
    Sources:
    • WishartDS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, et al. "DrugBank: a knowledgebase for drugs, drug actions and drug targets." Nucl Acids Res 2008, 36(suppl_1):D901-906; doi:10.1093/nar/gkm958.
    • 15. DrugBankPharmaBroswe web page: http://www.drugbank.ca/pharmabrowse#mainB.
  • Emerging Contaminants (EC):Humanity’s Chemical Footprints and Fingerprints
    They enter the environment by way of diffuse, complex, and interconnected networks fed by myriad numbers of people.
    ECs reflect:
    • The intimate, inseparable, and immediate connections of humans and the environment.
    • 16. The combinedactions, behaviors, and activities of individuals.
    • 17. The extensive interconnections and feedback loops between humans and the environment.
    • 18. ECs serve as direct measures of the types, extent, and magnitude of these connections.
  • PPCPs as Environmental Pollutants?
    PPCPsare a diverse group of chemicals comprising
    • All human and veterinary drugs (available by prescription or over-the-counter, including the new genre of “biologics”)
    • 19. Diagnostic agents(e.g., X-ray contrast media)
    • 20. “Nutraceuticals” (bioactive food supplements such as huperzine A)
    • 21. And other consumer chemicals, such as fragrances (e.g., musks) and sun-screen agents (e.g., 4-methylbenzylidene camphor; octocrylene)
    • 22. Also included are “excipients” (so-called “inert” ingredients used in PPCP manufacturing and formulation; e.g., parabens)
  • Beneficiaries & Stakeholders
    The topic of drug disposal is a deceivingly complex and exasperating topic.
    While it is but one of the many aspects of the larger issue of pharmaceuticals in the environment (PiE), drug disposal has proved to be the most visible and frustrating one to address. Recognized as a problem by the healthcare community in the 1960’s, only since roughly 2005 had any dialog and debate begun among an extraordinarily broad spectrum of communities:
    ► environmental science► healthcare (physicians, nurses, hospitals, long-term care facilities)► pharmaceutical industry (primarily via PhRMA)► pharmacy industry► insurance industry► local, state, & federal regulators and legislators(resulting in myriad proposed, rejected, and passed bills)► operators of water and wastewater treatment facilities► news media► the public► countless other stakeholders (especially numerous professional societies and trade associations).
    The primary federal involvement has been among: the Executive Office of the President (ONDCP), Department of Justice (DEA), FDA, and EPA.
  • 23. Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdf